Weight Loss

Weight Loss

Peptides researched for appetite regulation, fat metabolism, and body composition improvement. Includes GLP-1 agonists and metabolic peptides. Each compound links to its full dosing protocol.

Research Use Only. All dosing information is for educational purposes. Consult a licensed healthcare provider before making health decisions.

Semaglutide

GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glycemic control. One of the most studied peptides for weight management with significant clinical trial data.

Quick Dosing Reference (5 mg vial):
Route: Oral
Reconstitution: 2.0 mL bacteriostatic water → ~2.5 mg/mL concentration
Schedule: Weeks 1–4: 250 mcg → Weeks 5–8: 500 mcg → Weeks 9–12: 1000 mcg → Weeks 13–16: 1700 mcg

Tirzepatide

Dual GLP-1/GIP receptor agonist that targets two incretin pathways simultaneously. Demonstrated significant weight reduction in clinical trials, often exceeding semaglutide results.

Quick Dosing Reference (5 mg vial):
Route: Subcutaneous injection
Reconstitution: 2.0 mL bacteriostatic water → 2.5 mg/mL concentration
Schedule: Weeks 5–8: 5 mg 100 → Weeks 13–16: 10 mg 100 → Weeks 5–8: 5 mg 100 → Weeks 13–16: 10 mg 100

Retatrutide

Triple agonist targeting GLP-1, GIP, and glucagon receptors. Next-generation obesity peptide with potentially greater weight loss efficacy through three complementary metabolic pathways.

Quick Dosing Reference (5 mg vial):
Route: Subcutaneous injection
Reconstitution: 1.0 mL bacteriostatic water → ~5.0 mg/mL concentration
Cycle: Minimum 24 weeks; trials extended to 48 weeks
Schedule: Weeks 1–4: 2 mg 40 → Weeks 5–8: 4 mg 80 → Weeks 9–12: 6 mg 120 → Weeks 13+: 8 mg 160

AOD-9604

Modified fragment of human growth hormone (hGH 177-191) that stimulates lipolysis and inhibits lipogenesis without affecting blood sugar or growth. Targeted fat metabolism peptide.

Quick Dosing Reference (2 mg vial):
Route: Subcutaneous injection
Reconstitution: 3.0 mL bacteriostatic water → ~0.667 mg/mL (667 mcg/mL) concentration
Dose Range: 300–500 mcg once daily (gradual titration)
Cycle: 8–12 weeks; optional extension to 16 weeks
Schedule: Weeks 1–4: 300 mcg 45 → Weeks 5–12: 500 mcg 75 → Weeks 1–4: 300 mcg 18 → Weeks 5–12: 500 mcg 30
Research — Weight Loss:

5-Amino-1MQ

Small molecule NNMT inhibitor that increases cellular energy expenditure by boosting NAD+ and SAM levels. Researched for reducing fat cell size and promoting metabolic activity.

Quick Dosing Reference (10 mg vial):
Route: Oral
Reconstitution: 2.0 mL bacteriostatic water → 5 mg/mL concentration
Schedule: Weeks 5–6: 4 mg → Weeks 7–8: 5 mg → Weeks 5–6: 4 mg → Weeks 7–8: 5 mg
Research — Weight Loss:

Tesofensine

Triple monoamine reuptake inhibitor that suppresses appetite through serotonin, dopamine, and noradrenaline pathways. Originally developed as a neurological drug, repurposed for weight management.

Quick Dosing Reference:
Route: Subcutaneous injection or Oral

CagriSema

Fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist). Dual-pathway approach targeting both satiety and glucose metabolism for enhanced weight loss.

Quick Dosing Reference:
Route: Subcutaneous injection

All information is intended strictly for educational and research purposes. Not medical advice. Consult a licensed healthcare provider before making any health decisions.

Scroll to Top